Informax Announces the Release of Genomax Version 3.2.
BETHESDA, Md.--(BW HealthWire)--Nov. 7, 2001
InforMax, Inc. (Nasdaq:INMX), a leading global provider of bioinformatics software solutions, today announced the release of GenoMax(TM) version 3.2.
This new release contains significant enhancements to the GenoMax enterprise bioinformatics system, including the addition of Gene Expression Analysis II.
"Comprehensive and integrated software solutions are essential to enable sophisticated problem solving, data mining and efficient analytical processes." said Stephen Lincoln, Chief Scientific Officer and Executive Vice President of Product Development at InforMax. "The ongoing development of our GenoMax enterprise bioinformatics system affirms InforMax's commitment to advance the science of bioinformatics through the delivery of unique software and services that improve both the efficiency and effectiveness of the target discovery and validation process."
GenoMax version 3.2 enhanced features include an innovative high-performance engine for GenBank data storage, accelerated initial data loading and indexing, improved administrative capabilities, and enhanced scripting to improve end-user productivity and reduce administrative costs.
Additionally, GenoMax version 3.2 includes numerous new features in the Sequence Analysis and Protein-Protein Interaction Analysis modules.
Gene Expression Analysis II, the next generation of GenoMax gene expression software, features newly designed data import utilities and additional data visualization tools, which allow detailed data quality verification and provide powerful annotation capabilities for analysis of gene function.
The Gene Expression Analysis II module supports diverse gene expression data formats and provides customers with the industry's most comprehensive solution for analyzing and understanding gene expression information.
"GenoMax and the sophisticated analytical capabilities in the Gene Expression Analysis II module are key enablers for our work here at the University of North Carolina. The robust data import capabilities simplify the growing challenge of managing data commonly found with other gene expression analysis products," said David Fenstermacher, Director of Bioinformatics at the University of North Carolina.
Rapidly becoming the industry standard, GenoMax is an enterprise bioinformatics system that enables High-Throughput Research(TM) (HTR), InforMax's process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development.
This modular family of tools is designed to work with one or more types of genomic and proteomic data, and includes Sequence, Gene Expression, 3D Structure, Protein-Protein Interaction and Genome Analysis modules.
InforMax is the leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, InforMax products are used by over 1,800 research organizations and more than 28,000 individual scientists worldwide (as of September 30, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution.
Among InforMax's customers are 23 of the top 25 pharmaceutical companies. InforMax's mission is to support the scientific community in drug discovery and to better understand the causes of disease.
Our comprehensive portfolio of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining.
Our market-leading products include Vector NTI(R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM), a modular family of analysis programs for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at our Web site at http://www.informaxinc.com.
Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements.
Factors that could cause or contribute to differences include, but are not limited to, risks associated with the Company's operating losses and accumulated deficit and the prospect that the Company may not achieve or maintain profitability in the future, the Company's dependence for future revenues and its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, any disruption to the Company's operations or increase in its administrative costs associated with the Company's current executive management search and management transition and risks associated with InforMax's technologies and the need to keep pace with rapid technological change.
These factors and others are more fully described in the Company's annual report on Form 10-K and the most recent 10-Q, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook only as of the date given.
InforMax, the InforMax logo, Vector NTI, AlignX, BioPlot, and ContigExpress are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 7, 2001|
|Previous Article:||Pivotal Achieves Rapid Results for Meridian Energy New Zealand.|
|Next Article:||Time Warner Cable, Cincinnati Division Uses LiveWave ConvergenceCams for Viewing Rare Sumatran Rhino Baby; Baby Rhino and Mom Appearing Live on TV...|